DEPRECIATION &

AMORTIZATION^(b)

YEAR ENDED DECEMBER 31, 2011^(c)

Primary Care

Specialty Care and Oncology

Established Products and Emerging Markets

Animal Health and Consumer Healthcare

Total reportable segments

Nutrition and other business activities^(d)

Reconciling Items:

Corporate^(e)

Purchase accounting adjustments^(f)

Acquisition-related costs^(g)

Certain significant items^(h)

Other unallocated⁽ⁱ⁾

YEAR ENDED DECEMBER 31, 2010

Primary Care

Specialty Care and Oncology

Established Products and Emerging Markets

Animal Health and Consumer Healthcare

Total reportable segments

Nutrition and other business activities^(d)

Reconciling Items:

Corporate^(e)

Purchase accounting adjustments^(f)

Acquisition-related costs^(g)

Certain significant items^(h)

Other unallocated⁽ⁱ⁾

YEAR ENDED DECEMBER 31, 2009^(c)

Primary Care

Specialty Care and Oncology

Established Products and Emerging Markets

Animal Health and Consumer Healthcare

Total reportable segments

Nutrition and other business activities^(d)

Reconciling Items:

Corporate^(e)

Purchase accounting adjustments^(f)

Acquisition-related costs^(g)

Certain significant items^(h)

Other unallocated⁽ⁱ⁾

Income from continuing operations before provision for taxes on income.

Certain production facilities are shared. Depreciation is allocated based on estimates of physical production.

For 2011, includes King commencing on the acquisition date of January 31, 2011. For 2009, includes Wyeth commencing on the acquisition date of October 15, 2009.

Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the research and development costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.

Corporate for R&D expenses includes, among other things, administration expenses and compensation expenses associated with our research and development activities and for Earnings includes, among other things, administration expenses, interest income/(expense), certain compensation and other costs not charged to our operating segments.

Purchase accounting adjustments include certain charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment.

Acquisition-related costs can include costs associated with acquiring, integrating and restructuring newly acquired businesses, such as transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring (see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives for additional information).

Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our cost-reduction and productivity initiatives that are not associated with an acquisition, the impact of certain tax and/or legal settlements and certain asset impairments.

Includes overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment. In 2009, R&D expenses include approximately $550 million of Wyeth R&D expenses and Earnings include approximately $900 million of Wyeth earnings and $290 million of operating expenses incurred in Japan associated with our three biopharmaceutical operating segments, where allocation among the segments is not practicable.

Property, plant and equipment, net

United States

Developed Europe^(a)

Developed Rest of World^(b)

Emerging Markets^(c)

Consolidated

Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries.

Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand, and South Korea.

Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Middle East, Africa, Central and Eastern Europe and Turkey.